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Background: Hereditary Angioedema due to C1-Inhibitor deficiency (HAE types I and II) is a monogenic disease
characterized by sudden, self-limited episodes of cutaneous and mucosal swelling due to local deregulation of
vascular permeability. Despite its monogenic pattern of inheritance, HAE exhibits great clinical variability and low
genotype/phenotype correlation among those affected, which ultimately hinders therapeutic approach and
probably underlies yet unknown genetic and environmental factors.
Methods: We studied whole-genome RNA expression of PBMCs in three HAE type-I families (accounting for 40
individuals), 24 of which carry the same R472X mutation in the C1-Inhibitor gene and show large variability in terms
of disease expression. Those included in this study were analyzed according to the presence of mutation and/or
clinical symptoms.
Results: Instead of a single, common disease-associated expression pattern, we found different transcriptome
signatures in two of the families studied. In one of them (referred to as DR family), symptoms correlate with the
upregulation of 35 genes associated to the biological response to viral infections (including RSADs, OAS, MX and
ISG pathway members) and immune response. In another pedigree (Q family), disease manifestation is linked to the
upregulation of 43 genes with diverse functions, including transcription and protein folding. Moreover, symptoms-free
members of the Q pedigree display relatively higher expression of 394 genes with a wide diversity of functions.
Conclusion: We found no evidence for a common altered PBMC expression pattern linked to HAE symptoms in the
three families analyzed. All the data considered, differential gene expression in PBMCs do not seem to play a significant
role in the predisposition or protection against HAE in the basal -between crises- conditions analyzed. Although the
RNA expression pattern associated to the response to viral infections observed in the DR family supports the idea of
infectious diseases as a modifying factor for HAE severity, large-scale studies would be needed to statistically associate
such expression pattern to the development of this rare disease.
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Hereditary Angioedema (HAE, OMIM#106100) is a
rare genetic condition characterised by the occurrence
of severely incapacitating episodes of edema affecting
mucosal and submucosal layers. Edema attacks in HAE
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distribution, and reproduction in any mediumand can lead to life-threatening suffocation when there’s
involvement of the upper airways [1].
Inheritance of the disease is autosomal dominant due
to deleterious mutations in the serpin (Serum protease
inhibitor) C1-Inhibitor (C1-INH) (HAE types I and II)
or gain-of-function mutations in the gene coding for
the coagulation Factor XII (FXII) (HAE type III or
oestrogen-related HAE) [2]. Both genetic alterations
ultimately cause uncontrolled activation of the contact
and kinin-forming cascades, as evidenced by the extensive
activation of the factor XII–dependent pathways and
bradykinin release observed in HAE patients’ plasmas
[3,4]. Bradykinin, through its interaction with its specifictral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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major mediator of edema in these patients [5].
Systematic genetic screening has been performed in
HAE accounting for more than 200 mutations described
to date in the C1INH locus (responsible for the majority
of HAE cases). However, little or no genotype-phenotype
correlation has been detected [6]. Patients with HAE
carrying the same mutation exhibit large variability of
symptoms’ frequency and severity, even among siblings.
Such variability hinders therapeutic assessment and prob-
ably underlies yet unknown genetic and environmental
factors.
A potential source of clinical variation comes from the
poorly studied role of adaptive immunity in HAE. Although
some reports exist indicating abnormal distribution of
T lymphocyte surface receptors, reduced Langerhans
cell numbers and abnormal T- and B-cell counts in
HAE patients [7,8], little is known about how adaptive
immunity function and variation may modify the clinical
expression of the disease. More precisely, how innate and
adaptive immunity crosstalk in dealing with infection is
of particular interest, as viral and bacterial infections
are known to induce hives and edema under certain
pathological situations.
In the present report, we intended to study the
contribution of peripheral blood mononuclear cells
(PBMCs) to the clinical expression of HAE. For this
purpose, the RNA expression profile of PBMCs from 3
large HAE type I families was analyzed according to the
presence of mutation in the C1INH locus (R472X) and the
existence or frequency of clinical symptoms of angioedema.
Our results did not evidence common alterations in
the expression pattern of PBMCs in association to the
frequency and severity of disease manifestations in the 3
families. Instead, different expression profiles associated to
disease manifestation in each family, suggesting that
the PBMC compartment does not make a significant
contribution to HAE pathology in basal, non-inflammatory
conditions.
Materials and methods
Ethics statement
Biological sampling of human PBMCs was carried out
upon informed consent from the participants. The ethical
committee of Hospital La Paz gave approval to these
studies.
Patients and samples
HAE families were selected for these experiments on the
basis of two criteria: (i) the presence of a common mutation
in the C1INH locus segregating in the family and (ii) the
existence of a wide variability of symptoms’ frequency
among the affected individuals. Three non related families
carrying the R472X mutation were chosen: family AR(16 members), family DR (9 members) and family Q (15
members) (Table 1). In each family, the index case was
assigned number 0 (e.g. AR0), while the remaining family
members received correlative numbers depending on their
respective consanguinity (eg. AR1, AR2…). Additionally,
those family members not carrying the R472X mutation
were included in the study as healthy controls.
For the statistical analyses, patients were clustered in
clinical categories according to their disease severity
index, as previously described [6] (Table 1).
In the DR family and based on the available experimental
data dealing with the extent of androgen effects on C1-INH
synthesis [9], treatment was suspended two weeks before
blood sampling upon consent from their physicians.
As demonstrated by Gelfand and colleagues, the effect
of androgen treatment, as measured by the increase in
C1-INH and C4 serum levels, is maximal by one to two
weeks after the onset of the treatment but decreases rapidly
once it is stopped. For this reason, we set two weeks
after treatment removal as a convenient lapse of time
for sample collection. None of the patients referred
angioedema symptoms or other pathological conditions at
the time of sampling.
For validation purposes and in order to investigate the
permanence of the detected RNA expression patterns,
duplicated samples (first extraction at the time of the
microarray experiment and a second one, 10 months
later) were extracted and handled as recommended by
the manufacturer prior to processing. 2.5 mL of whole
blood were collected into each PAXgene™ Blood RNA
Tube (PreAnalytix® GmbH, Switzerland) using standard
methods. RNA was isolated from blood samples using
the PAXgene™ Blood RNA Kit (PreAnalytix). The quality
and integrity of RNA were assessed both by agarose gel
electrophoresis and bioanalyzer methods. Absorbances
at 260, 230 and 280 nm were measured and the A260/
280 and A260/230 ratios were considered adequate.
Additionally, EDTA-plasma samples were separated and
stored at -80ºC until used.
Labeling of RNA and microarray hybridization
One-Color Microarray-Based Gene Expression Analysis
Protocol (Agilent Technologies®, Palo Alto, CA, USA)
was used to amplify and label RNA. Briefly, 800 ng of total
RNA from patients and controls, were reverse transcribed
using T7 promoter primer and the Moloney murine
leukemia virus (MMLV) reverse transcriptase (RT). cDNA
was then converted to anti-sense RNA (aRNA) by
using T7 RNA polymerase which amplifies target material
simultaneously incorporating cyanine 3 (Cy3)-labeled CTP.
Samples were hybridized to a Whole Human Genome
Microarray™ 4x44K (G4845A, Agilent Technologies®). 1.65
micrograms of Cy3-labeled aRNA were hybridized for
17 hours at 65ºC in an Agilent hybridization oven
Table 1 Cohort descrip0074ion
Family code Gender Age Arg472Stop [C1-INH]
(mg/dL)
C1-INH activity
(% of NHP)
Symptoms Treatment
needed
Severity
score
Severity
degree
Family AR
ARO F 37 Yes 8.80 31.98 Yes Androgens 43 Severe
AR2 F 64 Yes 6.84 25.11 Yes Androgens 48 Severe
AR3 M 26 Yes 4.53 13.36 Yes Androgens 48 Severe
AR4 M 60 Yes 7.51 25.06 Yes Androgens 48 Severe
AR5 F 27 Yes <2.98 21.46 Yes No 24 Moderate
AR7 F 60 Yes 5.81 18.21 Yes Androgens 43 Severe
AR8 F 26 Yes 3.56 10.84 Yes Androgens 49 Severe
AR9 F 40 Yes 3.79 18.28 Yes No 12 Mild
AR10 M 53 Yes 7.05 34.24 No No 0 Asymptomatic
AR11 M 30 No 22.30 >100 - - - -
AR12 F 56 No 19.90 >100 - - - -
AR13 F 44 No 25.30 >100 - - - -
AR14 M 51 No 23.90 >100 - - - -
AR15 M 52 No 18.70 >100 - - - -
AR16 M 45 No 25.80 >100 - - - -
AR17 M 47 No 25.30 >100 - - - -
Family DR
DR0 F 52 Yes 3.65 24.8 Yes No 17 Mild
DR1 M 81 Yes 5.72 22.41 No ACE-i 0 Asymptomatic
DR3 M 32 Yes 5.07 26.70 No No 0 Asymptomatic
DR4 M 26 Yes 5.49 20.47 No No 0 Asymptomatic
DR5 F 17 No 24.30 >100 - - - -
DR6 M 75 No 21.50 >100 - - - -
DR7 M 41 No 24.90 >100 - - - -
DR8 F 39 No 18.00 >100 - - - -
DR9 F 37 No 20.30 >100 - - - -
Family Q
Q0 M 82 Yes 4.11 10.68 Yes Androgens 48 Severe
Q3 F 86 Yes 7.61 25.44 No No 0 Asymptomatic
Q4 F 57 Yes 11.80 40.63 Yes Androgens 26 Moderate
Q6 F 36 Yes 4.64 16.42 Yes Androgens 49 Severe
Q7 F 50 Yes <2.98 9.76 Yes No 25 Moderate
Q8 F 48 Yes 5.88 16.26 Yes No 28 Moderate
Q9 F 24 Yes 3.27 14.92 Yes No 48 Severe
Q10 F 71 Yes 6.28 17.23 No - 0 Asymptomatic
Q11 M 56 No 21.30 >100 - - - -
Q12 F 44 No 16.05 86.99 - - - -
Q13 M 38 No 26.40 >100 - - - -
Q14 F 47 No 20.30 >100 - - - -
Q15 F 75 Yes 6.34 18.00 Yes Androgens 25 Moderate
Q16 F 40 Yes 4.78 26.70 Yes Androgens 27 Moderate
Q17 M 45 Yes Yes Androgens 25 Moderate
Three HAE families were included in the microarray study: AR (16 members), DR (9 members) and Q (15 members). Treatment received by the patient and the
associated severity score at the time of sampling are shown. F: female; M: male; NHP: Normal Human Plasma; ACE-i: Angiotensin Converting Enzyme- inhibitors;
*: Not determined.
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concentration of 1x GEx Hybridization Buffer HI-RPM
(Agilent Technologies). Arrays were washed and dried out
according to manufacturer’s instructions (One-Color
Microarray-Based Gene Expression Analysis, Agilent
Technologies), and scanned at 5 mm resolution on an
Agilent DNA Microarray Scanner™ (G2565BA, Agilent
Technologies®) using the default settings for 4x44k format
one-color arrays. Images provided by the scanner were
analyzed using Feature Extraction software v10.1.1.1™
(Agilent Technologies®).
Preprocessing and data analysis
Raw signals were thresholded to 1 and quantiles nor-
malization [10] was performed using GeneSpring™ software.
Data were considered in the log2 scale. Default flags were
considered as absent, except saturated spots that were
flagged as marginal.
From the initial 34183 probes present in the chip,
20441 remained after applying the by-expression, by-flag
and by-error data filtering. Based on statistical outliers
criteria implemented in the Bioconductor package
ArrayQualityMetrics™, four samples showing excessive
variance among replicates (AR5, AR16, Q0 and Q4) were
removed for further analysis. Two different statistical
analyses were performed using the Limma™ package from
Bioconductor: (i) patients with mutation versus patients
without mutation, using the families as controlling
variable (random factor) and (ii) symptomatic versus
asymptomatic patients carrying mutation in each family.
Analysis of microarray results
The web-based pathways analysis tool IPA (Ingenuity
Systems®, www.ingenuity.com) was used to identify
biological pathways affecting the development of edema in
HAE. Gene expression was considered as significantly
upregulated when Fold Change (FC) was above 2. The
differentially expressed genes among symptomatic and
asymptomatic HAE patients were classified with gene
ontology (GO) analysis using the Database for Annotation,
Visualization and Integrated Discovery (DAVID) v6.7. In
this process, Fisher exact p values are used to measure the
gene-enrichment in annotation terms while Benjamini
scores provide an estimation of the False Discovery Rate
(FDR). FDR is defined as the expected proportion of false
positives among the declared significant results. Clustering
results were considered significant only when both the p
value and FDR statistics were below 0.05.
Real time PCR
TaqMan custom assay primers and probes (Roche
Diagnostics®, Barcelona, Spain) were designed by using
the manufacturer’s Universal Probe Library Assay Design
Center. In all cases, the RNA integrity and the specificityof RT-PCR amplified products were analyzed for by
agarose-gel electrophoresis prior to quantification. Analysis
of the results was performed with the standard curve
method and using the GAPDH and β-actin genes for
normalization. Equal amplification efficiencies were assessed
for target and reference genes.
Total RNA (500 ng) from patients and controls was
amplified using the SuperScript First Strand Synthesis
System™ with random hexameres (Invitrogen®, Carlsbad,
CA, USA). Real Time PCR was performed according to the
manufacturer’s protocols in a LightCycler® Carousel-based
System. All samples were loaded by duplicate and negative
controls (no-template) were included in every experiment.
RT-PCR experiments were conducted on RNA samples
isolated from two independent blood extractions. The
primers used for RT-qPCR validation were designed at
Universal Probe Library Assay Design Centre (http://
www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?
id=UP030000). The primers sequences were: RIG-I
(NM_014314.3) 5′TGGACCCTACCTACATCCTGA3′
(F) and 5′GGCCCTTGTTGTTTTTCTCA3′ (R);IFIT1
(NM_001548.3) 5′AGAACGGCTGCCTAATTTACAG3′
(F) and 5′GCTCCAGACTATCCTTGACCTG3′ (R);ISG15
(NM_005101.3) 5′GCGAACTCATCTTTGCCAGT3′
(F) and 5′AGCATCTTCACCGTCAGGTC3′ (R);OAS3
(NM_006187.2).Protein analysis in serum
In order to study the cytokines signature of the patients’
sera, selected protein markers were quantified using an
on-demand magnetic-bead-based multiplex immunoassay
from Bio-Rad (Bio-Plex Cytokine Group I 10-plex Assay;
Bio-Rad®, Hercules, CA, USA). The kit included beads,
probes and reagents for the quantification of IL-2, IL-4,
IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-17a, IFN-γ and TNF-α
in serum or plasma.Results
Microarray results
For the evaluation of the results, a threshold of Fold
Change (FC):2 was used in order to provide a conservative
foundation for further interpretations. Overall analysis of
the microarray outcome did not evidence alterations in
the expression pattern of a single pathway in the HAE
symptomatic individuals from our cohort. Instead, it
suggests the involvement of different pathways in two
of the families studied. Age and sex showed no major
association to clinical frequency and severity in the series.
The experimental population was stratified in subgroups
according to the “severity index” criteria and analyzed
accordingly. Only those comparisons reaching significance
are shown.
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symptomatic patients
Genes exhibiting altered patterns of expression in each
family are enlisted in Table 2.
Family DR
In the DR family, DR0 is a 52-year-old woman suffering
from 1-3 cutaneous edema episodes per year in the
absence of treatment. Her mutation-carrying relatives
DR1, DR3, DR4 (three males of ages ranging from 26 to
81) have been free of symptoms for the last two years or
longer. None of the three males is receiving HAE-related
treatments and, what is more, DR1 has remained asymp-
tomatic even during ACE-i treatment, which is a potent
edema-precipitating drug in HAE patients [11].
Analysis of the transcriptome in the DR family revealed
significant upregulation (FC > 2; adjpvalue < 0.05) of 35
genes in DR0, 27 of which are upregulated above 4FC
(Table 2). Top hits in this patient are: RSAD2, IFIT1,
IFI44L, CMPK2, ISG15, HERC5, OAS3 and IFI44.
Validation of the results was performed by RT-qPCR
quantification of ISG15, IFIT1, OAS3 and RIG-I in
DR family members (correlation coefficient R2:0.8327)
(Figure 1). Among the remaining upregulated genes in
DR0, the RNA helicase RIG-I (FC: 3,68) is relevant
because it is considered a very specific signature of the
presence of virus-derived RNA species into host cells
[12,13]. Gene Ontology (GO) analysis confirmed enrich-
ment of GO terms related to the biological response to
virus (pvalue:7. 3 × 10-7; FDR:1.2 × 10-4), RNA binding
(pvalue: 2.0 × 10-4; FDR:1.5 × 10-2) and endoplasmic
reticulum-associated catabolic process (pvalue: 3.8×10-2;
FDR:4. × 10-2). We did not identify transcripts significantly
downregulated above the imposed threshold of -2FC in
DR0 as compared to the remaining DR family members.
The complete raw data are accessible as Additional file 1:
Table S1, Additional file 2: Table S2, Additional file 3:
Table S3).
We also measured cytokines’ levels in the sera of DR
family members in two independent samples obtained in
a 10 months interval. In both measurements, DR0
exhibited significantly higher expression of IL4, IL5 and
IL8 as compared to healthy controls and symptoms-free
relatives (with or without mutation in the C1INH locus)
(Figure 2). This cytokine expression pattern suggests a
Th2 response and, therefore, the involvement of humoral
immunity. IL4 stimulates B cells and induces immuno-
globulin class switching to IgE. It also has a role in chronic
inflammation and wound repair by modulating the activity
of macrophage subpopulations. IL5 is produced by Th2
and mast cells. It is involved in B cell growth stimulation,
immunoglobulin production and activation of eosinophils.
As such, its overproduction has been associated to allergic
disease and asthma [14]. IL8 is a key mediator ofinflammation. It is produced mainly by macrophages,
endothelial and epithelial cells, although it can be secreted
by a variety of cells upon TLR stimulation. It promotes
chemotaxis in neutrophils and maintains proinflammatory
conditions by inducing further increase in oxidant stress
mediators, thus being implicated in chronic inflammatory
diseases [15].
Whether or not this cytokine profile is directly related
to the gene expression pattern observed in the microarray
of the patient is beyond the score of this paper. But taking
under consideration the outcome of the microarray in
DR0, the fact that similar results were obtained in the
quantification of serum cytokines in two time-elapsed
samples, and the absence of infectious manifestations in
the patient, the picture is suggestive of a chronic, asymp-
tomatic process. By analyzing the patient’s serum anti-
bodies, we discarded a putative Influenza infection as
causative of the gene expression pattern observed in DR0
(data not shown).
All considered, the rationale underlying these results
may be that, in the DR family, long-lasting, chronic viral
infections are a major triggering factor of angioedema.
Furthermore, it is feasible that genetic variation in one or
several genes involved in the immune response against
viruses and immune system regulation could influence
both the course of infection and the development of HAE
symptoms.
On the other hand, the three asymptomatic males in
the DR family exhibit upregulation of 32 transcripts
related to diverse biological functions that do not constitute
significant functional clusters, but share functional links
among them. That is the case of OLIG1 and OLIG2
transcription factors, which are expressed mainly during
central nervous system development [16], and RAVER
and PTBP1, both implicated in binding to polypyrimidine
tract sequences and regulating the expression of alternative
splicing forms [17].
Family Q
Two members of this family carrying the R472X substitu-
tion in C1-INH (Q3 and Q10) are asymptomatic and do
not require specific treatment for HAE. Examination of
the transcriptome in the asymptomatic individuals in this
family reveals relative upregulation of 394 transcripts
whose clustering, according to the transcripts’ associated
biological processes, renders only one significant group of
29 genes with “Transcriptional activation activity” (pvalue:
5.7 × 10-4; FDR: 7.1 × 10-2) (Table 2). Within this set of
genes, IL17F is upregulated above 4fold, which could be
related to the induction of proinflammatory responses;
however, it could not be measured in the patient’s plasma.
Another consistent set of genes upregulated in
asymptomatic mutation carriers from this family which is
associated to “Structural molecule activity” is composed
Table 2 Microarray results
Family DR Genes upregulated IH the symptomatic palielit DRO
Gene FC Adjpvalue Description
Type I Interferon signaling pathway
and /or Response to virus
p value:7.3 × 10-7
FDR: 1.2 × 10-4
ISG15 11.87 0.0012 ISG15 ubiquitin-likemodifier(ISG15). [NM_005101]
HERC5 11.63 0.0094 hect domain and RID 5 (HERC5). [NM_U 16323]
OAS3 11.00 0,0094
2’-5’-oligoadenylate synthetase 3, l00kDa (OAS3)
[NM_006187]
IFI44 10.70 0,0318 interferon-induced protein 44 (IFI44). [NM_006417]
1F1141. 17.03 0.0267
interferon-induced protein 44-like (IFI44L), mRNA
[NM_006820]
MXI 9.25 0,0241 myxovirus resistance 1 (MX1), [NM_002462]
1F16 8.57 U.U1M
Interferon, alpha-inducible protein 6 (IFI6) variant 3
[NM_022873]
IFIT3 861 00588
interfernn-indnced protein with tetratricnpeptide
repeals 3 (IFIT3). [NM_00 1549]
IFIT2 7.26 0,0096
interferon-induced protein with tetratricopeptide
repeats 2 (IFIT2), [NM_00 1547]
OASL 7.21 0,0485
2’-5’-oligoadenylate synthetase-like (OA.SL), variant 1,
[NM 0037331]
USP18 6.23 0,0080 ubquitin specific peptidase 18 (USP18), varient 1,
[NM_017414]
OAS2 5.89 0, 050 2’-5’-oligoadenylate synthetase 2 69/71/kDA (OAS2),
variant 3, [NM_001032731]
XAF1 4.96 0,0116 XIAP associated factor 1 (XAF1), variant 1, [NM 017523]
RSAD2 29.85 0,0128 radical S-alenosyl methionine domain containing 2
(RSAD2 [NM_0S0657]
IFIT1 20.25 0,0241 interferon-induced protein with tetratricopeptide
repeats 1 (IFIT1), [NM 001548]
IFIT35 2.71 0.050 interferon-induced protein 35 (IF135) [NM 005533]
Endoplasmic reticulum unfolded protein response
pvalue :3.8 × 10-2
FDR: 4 × 10-2
HSP90AB1
7.84
1,35E-06
heat shock protein 9OkDa alpha, class B member 1
(HSP9OAB 1) [NM 007355]
DERL3 9.92 0,0116 Derl-lilce domain family, member 3 (DERL3), variant 3,
rnRNA [NM_198440]
Nucleic acid binding and/or Response to virus
pvalue: 2.0 × 10-4
FDR1.5 × 10-2
RIG-1 3.68 0,0496 retinoic acid inducible gene I (RIG-I) [NM_014314]
DHX58 3.23 2,44E-05 DEXH (ASp-Glu-X-His) box polypeptide 58 (DHX58),
[NM_024119]
ZBP1 3.36 0,0012 Z-DNA binding protein 1 (ZBP1), variant 1, [NM 030776]
EIF2AK2
4.79 0,0 182
eukaryotic translation initiation factor 2-alpha kinase 2
(EIF2AK2), [NM_002759]
PARP12 2.50 0,050 poly (ADP-ribose Polyrnerace family. member 12 (PARP12).
[NM_022750]
Other
CMPK2 14.02 0,0036 cytidine monophosphate kinace 2. mitochondrial
(CMPK2L [NM_207315]
LAMP3 8.28 0,0128 lysosornal-acsociated membrane protem 3 (LAMP3),
[NM_0 14398]
SPATS2T 5.77 0,0080 spermatogenisis associated serine-rich 2-like (SPAT2L)
[NM_001100422]
USP4I 4.53 0,0182 partial mRNA for ubiquitin-specific protease 41
(USP41 gene). [AJ586979]
PROM2 5.73 0,0406 prominin 2 (PROM2) variant 3, [NM_144707]
DNHD1 5.58 0,0241 dynein heavy chain domain 1 (DNHD1), variant 2,
[NM 173589]
L0C64494 5.09 0,0249 cDNA FLJ455O9 fis, clone BRTHA2020811. [AK127417]
IFIT5 4.86 0.0 128 interferon-induced protein with tetratricopeptide repeats
5 (IFIT5), [NM0 12420]
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Table 2 Microarray results (Continued)
LY6E 4.44 0,0101 lymphocyte antigen 6 complex. locus E çLY6E), variant I,
[NM U02.s4b]
INPP5F 3.48 0,0122 inosito1po1yphnphale-S-phnsphalaceF(fNPPSF) variant 1
[N1\it 014917]
TTC21A 3.14 0,0462 tetratricopeptide repeat domain 21A (TTC21A), variant 2,
[NM 145755]
FGD2 2.71 0,0560 FYVE, RhoGEF and PH domain containing 2 (FDG2)
[NM_173558]
Family Q Genes upregulated in asymptomatic versus severelyaffected individuals
Biological process Gene FC Adjpvalue Description
SMAD5 5.35 0.0140 SMAD family member 5 (NM_001001419)
KLF15 3.58 0.0142 Kruppel-like factor 15 (006814)
ATXN7 10.26 0.0144 ataxin 7 (NM_001128149)
UTF1 4.59 0.0158 undifferentiated embronic cell transcription factor
(NM_003577)
ALX4 4.00 0.0179 ALX homeobox 4 (ENST00000329255)
MAFA 3.65
0.0182 v-maf musculoaponeuroticfibrosarcoma oncogene
homolog A(NM_201589)
RARA 17.22 0.0219 retinoic acid receptor, alpha (NM_001024809)
Tead1 5.20 0.0220 TEA domain family member 1(NM_021961)
NEUROG3 5.51 0.0237 neurogenin 3 (NM_020999)
DYRK1B 4.48
0.239 dual-specificity tyrosine -(Y) phosporylation regulated
kinese 1B (NM_004714)
EIE5AL1 23.96
0.2399 eukaryotic translation initiation factor 5A
(NM_001099692)
Transcription activator activity
pvalue : 5.7 × 10-4
FDR: 7.1 × 10-2
MYOG 16.54 0.0239 myogenin (mygenic factor 4 ) (NM_002479)
GLI2 6.86 0.0258 GLI family zinc finger 28 (NM_005270)
TFE3 3.48
0.0272 transcription factor binding to IGHM enhancer
3(NM00651)
EVXI 7.82 0.0273 even-skipped homebox 1 (NM_005163)
FOXC1 4.44 0.0291 forkhead box C1 (NM_001989)
HRH1 2.91 0.0303 histamine receptor H1 (NM_001098213)
AKT1 4.76
0.0303 v-akt murine thymoma viral oncogene homolog 1
(NM_005163)
CTRC1 7.89
0.3311 CREB regulated transcription coactivator 1
(NM_001098482)
CARD11 7.10 0.0318
caspase recruitement domain family, member 11
(AK097139)
CD80 3.53 0.0335 CD80 molecule RG Homo sapiens (NM_001042454)
IL17F 4.13 0.0351 interleukin 17F (NM_021784)
RARG 7.08 0.369 retinoic acid receptor, gamma (NM_000966)
TGTBI111 4.38 0.0369 transforming growth factor beta
FOXA2 2.89 0.0411 forkhead box A2 (NM_021784)
BHLHE23 5.27 0.0420 basic helix-loop-helix- family, member e23 (NM_080606)
Structural molecule activity
pvalue: n.s.
FDR: n.s.
SPTBN2 3.36 0.0084 spectrin, beta, non-erythocytic 2 (NM_006946)
AGRN 5.02 0.0088 agrin (NM_198576)
CLDN19 3.82 0.0094 claudin 19 (NM_001123395)
KRT8 3.48 0.0102 keratin 8 (NM_002273)
COL5A1 6.53 0.0142 collagen, type V, alpha 1 (NM_000093)
KRTAP1 3.54 0.00170 keratin associated protein 1-3 (NM_030966)
KRT7 8.75 0.0179 keratin 7 (NM_005556)
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Table 2 Microarray results (Continued)
EMILIN1 3.04 0.0186 elastin mocrofibril interfacer 1 (NM_007046)
COL27A1 6.30 0.0204 collagen, type XXVII, alpha 1 (NM 032888)
MUC6 4.66 0.0271 mucin 6 (NM_005961)
KRT1 6.10 0.0307 keratin 1 (NM_006121)
KRT73 5.67 0.0307 lamin A/C (NM_170707)
MUC3B 4.89 0.0311 mucin 3B, cell surface associated (ENST00000379458)
COL11A2 8.72 0. 0369 collagen, type XI, alpha 2 (NM_001163771)
EVPL 4.72 0.0401 evoplakin (NM_170707)
KRT81 5.89 0.425 keratin 81 (NM_002281)
CHAD 3.72 0.0473 chondroadherin (NM_001267)
LAMC3 4.26 0.0473 laminin, gamma 3 (NM_006059)
Gene ontology was performed using the Database for Annotation, Visualization and Integrated Discovery (DAVID). For this analysis, biological processes associated to each
transcript were used to establish significant functional categories among the top results in each family. Ontology results from the DR (2) and Q families (2) are shown.
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collagen genes and 2 laminin genes) although pvalue
and FDR score of this cluster do not reach statistical
significance.
On the other hand, when compared either with
asymptomatic or control individuals, severely affected
members of the Q family exhibit an expression pattern
characterized by the upregulation of 43 genes which take
part in diverse biological processes. Nevertheless, no
significant functional cluster could be detected.
Family AR
Most of the members carrying the R472X substitution in
this family (AR0, AR2, AR3, AR4, AR5, AR7, AR8, AR9)
suffer frequent and mild-to-severe abdominal and/or
cutaneous symptoms of HAE. Among them, AR2, AR3
and AR4 are under treatment with attenuated androgensFigure 1 RT-qPCR validation of the microarray results in the DR famil
mRNAs from two independent samples are shown A). Correlation between
used to verify significant differences among groups. *** denotes pvalue < 0(Danazol) while their remaining relatives, who experience
milder symptoms, do not receive any prophylactic
treatment. Only one member of this family, AR10, a
53-year old man, has never manifested clinical signs of
HAE nor has been treated for the disease and his diagnosis
was achieved only when his affected daughter was studied.
No significant disease-modifying factors could be identified
in this family.
Discussion
The aim of the present study was to investigate the
influence of the PBMC transcriptome on the predispos-
ition to or protection from developing HAE symptoms.
The results presented shed more light on the interface
between innate and adaptive immunity in the context of
C1-INH deficiency and question the role of local C1-INH
synthesis by PBMCs in HAE patients. Effectively, not they. Averaged results of the quantification of IFIT1, ISG15, OAS3 and RIG-I
RT-qPCR and microarray results B). The Mann-Whitney statistic was
.001.
Figure 2 Quantification of cytokines in plasma of the DR family. Measurement was performed with a magnetic-bead-based multiplex
immunoassay (Bio-Rad). Averaged results from two independent samples are shown. The medium bar in the box and whisker plots corresponds
to the median from two independent samples. In both assays, plasma from patient DR0 had significantly higher concentrations of IL4, IL5 and IL8
than control plasmas and asymptomatic patients. IL6 was also higher in DR0, although it did not reached significance. Statistical analyses were
performed with the Mann-Whitney test.
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molecules classically implicated in the pathogenesis of
HAE like Angiotensin Converting Enzyme (ACE),
Bradykinin Receptors 1 and 2, (BDKR1, BDKR2) or
Aminopeptidase P (APP) showed any statistical effect
on the frequency of HAE attacks [18,19]. In agreement with
that, instead of a common disease-associated signature,
PBMCs from the three families analyzed exhibit different
expression patterns linked to their symptoms. What is
more, the most significant results in the present work
were obtained in the symptomatic individual from the
DR family, whose expression profile strongly suggests
host response to viral infection as the major disease-
precipitating factor. This facts might indicate that local
protein synthesis by the PBMC milieu plays only a
modest role under the circumstances analyzed here (in
a free-of-symptoms period).
This interpretation of the results differs from reports
by Klausegger et al. describing a child affected of Evans
syndrome and HAE, whose angioedema symptoms were
clinically and biochemically cured by stem cell bone
marrow transplantation [20]. Although the authors report
a complete cure of HAE signs which is supported by the
rising in serum C1-Inh function from 5-50% to 84% of
control values, circulating levels of C4 in the patient
are still at the lower limit of normality two years aftertransplantation (11.2 mg/dL). Besides, he is still in his
childhood years, and given that HAE tends to manifest
or worsen at puberty, a longer follow-up period would
be recommendable to confidently assess full recovery
of normal C1-Inh synthesis. On the other hand, the
apparent discrepancy between the case reported by
Klausegger et al. and the results presented here could in
fact reflect a lack of statistical power in our experimental
design, either by the reduced sample size or due to the
small effect of the investigated disease-modifiers in the
PBMCs. In that case, a more robust design of the
study (e.g. RNA analysis of patients in the course of
an attack versus asymptomatic patients) might overcome
the statistical difficulties. Alternatively, the interrogation
of a different tissue -like biopsy derived endothelial cell
or hepatocyte cultures- could be a more appropriate
experimental setting, although the difficulty of obtaining
an adequate sample size from patients’ biopsies is evident.
In the case of the present study, samples from different
tissues were initially considered, but PBMCs were chosen
as the most affordable option.
Regarding the results obtained in the DR family, we
measured RNA expression of upregulated genes ISG15,
IFIT1, OAS3 and RIG-I by RT-qPCR with TaqMan
primers and probes. In all cases, the results of microarray
and RT-qPCR experiments correlated adequately, for an
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did not validate the microarray results at the protein level
due to the lack of a convenient commercial kit, but we did
intend to characterize the cytokine profile in the sera from
the DR family members with a magnetic-bead-based
multiplex immunoassay. The results from two inde-
pendent samples demonstrated higher serum levels of IL4
(pvalue:0.004), IL5 (pvalue:0.007) and IL8 (pvalue:0.007) in
the symptomatic patient DR0 as compared to both healthy
controls and asymptomatic DRs. Given that the two
samples analyzed were obtained within a 10 months
interval and based on the microarray results, this cytokine
profile could reflect chronic inflammation or a long-lasting,
asymptomatic infection in the patient.
The role for adaptive immunity in the development of
HAE has remained controversial along the years. HAE
symptomatology is accompanied by a higher prevalence
of autoimmunity including glomerulonephritis, lupus-like
disorders and Sjögren’s syndrome [21]. In the context of a
C1-INH deficiency, abnormal activation of complement
via the classical pathway consumes the initial components
of the cascade and may expose HAE patients to an
increased risk of immune-complex disease, as seen in the
C2 or C4 deficiencies.
Several reports exist that describe immunoregulatory
alterations in HAE ranging from autoimmunity (glomer-
ulonephritis and Sjögren’s syndrome being the most
frequent conditions) to unbalanced T cell subpopulations
or polyclonal B cell activation [22]. However, while some
recent publications in the field found a higher prevalence
of autoimmune disorders but failed to detect further
immunoregulatory defects [23], others have shown
abnormalities in the biology of HAE memory B cells
that provide a rationale for the high prevalence of
autoimmunity observed in this disease [24]. The latter
include higher overall phosphotyrosine levels and
enhanced expression of CD69, CD5, CD21 and Toll-Like
Receptor 9 (TLR-9) in memory B cells of HAE patients as
compared to controls. What is more, Kessel and colleagues
demonstrated that TLR-9 expression was higher in the
memory B cells of those HAE cases where autoantibodies
were also present, suggesting that the enhanced production
of autoantibodies in this disorder is most probably due to
increased B cell activation.
The implication and importance of adaptive immunity
in the development of HAE is also supported by clinical
observations in series of patients. Cedzyński and colleagues
analyzed the effect of infectious disease on the clinical
scores for the frequency and severity of HAE symptoms.
Their results, although not reaching significance, showed
that infection by Helicobacter pylori and Hepatitis B virus
may slightly worsen HAE pathology [25]. Infection by H.
pylori has also been reported to cause acquired C1-INH
deficiency in a case report by Farkas and colleagues. Theauthors attributed this effect to the excessive consumption
of complement by antibodies directed against H. pylori.
Moreover, successful eradication of the pathogen in
the patient resulted in a fivefold reduction in- or
complete disappearance of HAE symptoms [26]. Thus, it
is predictable that infectious diseases resulting in
enhanced antibody response and the formation of
immune complexes may trigger the overuse of already
reduced C1-INH in HAE patients [27].
In contrast to the DR family, symptomatic members
from the Q family show no evidence of viral infection as a
noteworthy precipitating factor. Instead, the transcriptome
signature observed in these individuals is more complex
and consists of 43 genes upregulated in the severely
affected Q members versus 394 transcripts showing higher
expression in their symptom-free relatives. Given the high
number of genes with altered expression in this family
and their diverse clustering options, it is difficult to give a
simple interpretation to the results. As shown in Table 2,
gene ontology analysis renders only one significant cluster
of genes associated to transcription activator activity.
Regarding the AR family, where no significant hit was
detected, it is likely that the high proportion of ARs
receiving androgen prophylactic treatment at the time of
sampling (5 out of 8 patients) would wipe away the
individual differences of gene expression and explain the
lack of overall results in the family.
The present results arise from the study of a very
reduced number of HAE families harbouring the same
HAE type I mutation. It is likely that part of the expression
profiles characterized in this cohort represent only
patient- and/or mutation-specific signatures, rather than
general mechanisms of the disease.
All considered, our data did not provide new major
evidences concerning the role of PBMCs in the develop-
ment of HAE in basal, out of crises, situations. The strong
association between asymptomatic viral infection and
HAE severity observed in the DR family supports the idea
of infectious diseases as a major precipitating factor, which
is endorsed by abundant clinical observations [6,24].
However, data from a single family cannot be extrapolated
further and large scale, systematic screening studies would
be needed to statistically associate the mRNA expression
pattern observed in the DR0 patient with predisposition
to HAE flares.Additional files
Additional file 1: Table S1. DR family. Genes upregulated in
Asymptomatic versus Control individuals.
Additional file 2: Table S2. DR family. Genes upregulated Symptomatic
versus Control individuals.
Additional file 3: Table S3. Q family. Genes upregulated in
Asymptomatic versus Control individuals.
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